Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: A randomized clinical trial in Beijing

Chinese Medical Journal

Volumn 116, Issue 8, 2003, Pages 1127-1133

  Zheng, Shurong ^a   Wu, Yiyong ^b   Zhang, Zhonglan ^c   Yang, Xin ^a   Hui, Ying ^b   Zhang, Ying ^c   Chen, Shuling ^a   Deng, Wenhui ^b   Liu, Hui ^c   Ekangaki, Abie ^d   Stocks, Jodie ^d   Harper, Kristine ^d   Liu, Jianli ^c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Bone mineral density; Lipids; Metabolism; Postmenopause; Raloxifene

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; BIOLOGICAL MARKER; CALCICHEW D; CALCIUM; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; PEPTIDE DERIVATIVE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL; VITAMIN D;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CEREBELLUM INFARCTION; CHINA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; FEMALE; HEADACHE; HEART MUSCLE NECROSIS; HIP; HOT FLUSH; HUMAN; LEG CRAMP; LIPID BLOOD LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UTERUS MYOMA; VERTEBROBASILAR INSUFFICIENCY;

AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CHINA; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0041328600     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Compston JE. Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects. Reprod Med Rev 1994;3:209-224.
2. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277:1140-1147.
3. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998;90:814-823.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288:321-333.
5. Rees MC. The need to improve compliance to HRT. Br J Obstet Gynaecol 1997;104:Suppl16:1-3.
6. Spencer CP, Cooper AJ, Whitehead MI. Management of abnormal bleeding in women receiving hormone replacement therapy. BMJ 1997;315:37-42.
7. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Hormone Res 1997;48:155-163.
8. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
9. Delmas P, Ensrud K, Adachi J, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis. 4-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617.
10. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
11. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-1754.
12. Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstetr Gynecol 2000; 95:95-103.
13. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281: 2189-2197.
14. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-134.
15. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.
16. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85:214-218.
17. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287:847-857.
18. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 1992; 2: 285-289.
19. Johnston CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, andserum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-3450.
20. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-1464.
21. Hurley D, Kholsa S. Subspeciality clinics: endocrinology, metabolism, and nutrition. Clin Proc 1997;72:943-949.
22. Ravn P, Hetland ML, Overgaard K, et al. Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy X-ray absorptiometry. J Bone Miner Res 1994;9:1975-1980.
23. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind randomized trials in 12 000 postmenopausal women. Program/Proceedings of the American Society of Clinical Oncology 34th Annual Meeting May 16-19, P122a. 1998: WB Saunders Company/Mack Printing Group.